Physician profile
Karan Patel
NPI 1861887473
$2,828.44
in general payments reported to CMS, 2019-2025
12 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2023: $410 · 2024: $278 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,243.77 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Johnson & Johnson Surgical Vision, INC. | $401.60 | 2019-2023 | Whitestar Phaco Handpiece |
| Amgen INC. | $281.01 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $186.19 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $170.97 | 2023-2025 | Miebo, Xiidra |
| Topcon Healthcare, INC. | $162.65 | 2025 | |
| Novartis Pharmaceuticals Corporation | $159.83 | 2019 | |
| Sun Pharmaceutical Industries INC. | $75.60 | 2023-2025 | Cequa |
| Glaukos Corporation | $48.37 | 2024 | Radius, Idose |
| Oyster Point Pharma, INC. | $45.06 | 2023-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $38.39 | 2024 | Xdemvy |
| Abbvie INC. | $15.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.